FINWIRES · TerminalLIVE
FINWIRES

$ADPT

6 stories mentioning ADPTUpdated 11d ago

Every FINWIRES story that references ADPT, newest first.

Insider Trading

Adaptive Biotechnologies Insider Sold Shares Worth $2,389,164, According to a Recent SEC Filing

Francis Lo, Chief People Officer, on July 15, 2026, sold 105,762 shares in Adaptive Biotechnologies (ADPT) for $2,389,164. Following the Form 4 filing with the SEC, Lo has control over a total of 233,213 common shares of the company, with 230,713 shares held directly and 2,500 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1478320/000178066026000019/xslF345X05/form4.xml

$ADPT
Insider Trading

Adaptive Biotechnologies Insider Sold Shares Worth $8,501,149, According to a Recent SEC Filing

Harlan S Robins, Chief Scientific Officer, on July 02, 2026, sold 386,240 shares in Adaptive Biotechnologies (ADPT) for $8,501,149. Following the Form 4 filing with the SEC, Robins has control over a total of 1,019,658 common shares of the company, with 1,019,658 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1478320/000178085126000015/xslF345X05/form4.xml

$ADPT
Treasury

Adaptive Biotechnologies Issues $345 Million Convertible Notes

Adaptive Biotechnologies (ADPT) said late Monday it has issued $345 million of 0% convertible senior notes due 2031, including the full exercise of an over-allotment option.Net proceeds were used among others for capped call transactions, share repurchase, and for the repayment of the OrbiMed purchase agreement, the company said in a filing.

$ADPT
Insider Trading

Adaptive Biotechnologies Insider Sold Shares Worth $1,847,942, According to a Recent SEC Filing

Harlan S Robins, Chief Scientific Officer, on June 15, 2026, sold 106,160 shares in Adaptive Biotechnologies (ADPT) for $1,847,942. Following the Form 4 filing with the SEC, Robins has control over a total of 1,405,898 common shares of the company, with 1,405,898 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1478320/000178085126000013/xslF345X05/form4.xml

$ADPT
Wire

Adaptive Biotechnologies Weighs Separation of Immune Medicine Unit; Shares Fall After Hours

Adaptive Biotechnologies (ADPT) is evaluating strategic and structural alternatives for its immune medicine segment in a plan to separate the business from its minimal residual disease division.A decision on the separation is expected by year-end, the company said Monday in a statement.Adaptive shares fell 5.6% in after-hours trading.

$ADPT
Insider Trading

Adaptive Biotechnologies Insider Sold Shares Worth $1,008,622, According to a Recent SEC Filing

Julie Rubinstein, President and Chief Operating Officer, on April 17, 2026, sold 69,061 shares in Adaptive Biotechnologies (ADPT) for $1,008,622. Following the Form 4 filing with the SEC, Rubinstein has control over a total of 395,146 common shares of the company, with 395,146 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1478320/000178066426000028/xslF345X05/form4.xml

$ADPT

Track with the FINWIRES app suite

FolioX
FolioX
Track ADPT in your portfolio
WheelAI
WheelAI
Analyze ADPT options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ADPT